The global overactive bladder treatment market is expected to witness significant growth in the coming years. According to the latest market research report, the market is projected to reach USD 4.2 billion by 2027, growing at a CAGR of 3.6% during the forecast period from 2022 to 2027. This growth can be attributed to several factors such as the rising prevalence of overactive bladder syndrome across the world and the launch of novel drugs with lesser side-effects.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219938791

In addition, the adoption of technologically advanced treatment options for OAB treatment is also expected to support market growth in the coming years. This has led to increased competition among the market players, with several companies adopting various strategies to sustain market competition.

Astellas Pharma, Teva Pharmaceutical Industries, Pfizer, Medtronic, AbbVie, Viatris, Hisamitsu Pharmaceutical, Johnson Johnson Services, Endo Pharmaceuticals, and others are some of the prominent players operating in the global overactive bladder treatment market.

Astellas Pharma, a Japanese multinational pharmaceutical company, is one of the leading players operating in the overactive bladder treatment market globally. The company provides two major drugs, Betanis/Myrbetriq/BETMIGA and VESIcare. Myrbetriq is one of the most prescribed medications for overactive bladder disorders.

Pfizer, a leading global pharmaceutical company, develops medicines for a wide range of therapeutic areas, including overactive bladder treatment. The company markets its product, TOVIAZ, under the Internal Medicine segment of the Biopharma business.

AbbVie, a diversified research-based biopharmaceutical company, has a comprehensive product portfolio that has leadership positions across various therapeutic areas. The company provides Enablex, extended-release tablets for overactive bladder treatment.

Request Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=219938791

In conclusion, the global overactive bladder treatment market is projected to witness significant growth in the coming years, with several market players adopting strategies to sustain market competition. The launch of novel drugs with lesser side-effects and the adoption of technologically advanced treatment options for OAB treatment are also expected to support market growth in the coming years.

Related Links

https://www.marketsandmarkets.com/Market-Reports/overactive-bladder-treatment-market-219938791.html

https://www.marketsandmarkets.com/PressReleases/overactive-bladder-treatment.asp

https://www.marketsandmarkets.com/ResearchInsight/overactive-bladder-treatment-market.asp